Get the Stockscreener App
2.83
1.98%
0.055
Boundless Bio Inc stock is traded at $2.83, with a volume of 108.95K.
It is up +1.98% in the last 24 hours and up +15.04% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
See More
Previous Close:
$2.775
Open:
$2.78
24h Volume:
108.95K
Relative Volume:
0.09
Market Cap:
$64.38M
Revenue:
-
Net Income/Loss:
$-55.99M
P/E Ratio:
-1.1314
EPS:
-2.5013
Net Cash Flow:
$-47.60M
1W Performance:
-2.08%
1M Performance:
+15.04%
6M Performance:
+150.44%
1Y Performance:
+141.88%
1-Day Range:
$2.735
$2.84
1-Week Range:
$2.72
$2.97
52-Week Range:
$0.9612
$2.97
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
2.83 | 63.24M | 0 | -55.99M | -47.60M | -2.5013 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
Boundless Bio (BOLD): ADAR1 Capital discloses 8.8% beneficial ownership stake - Stock Titan
Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership - Stock Titan
Boundless Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Boundless Bio Inc (BOLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Boundless Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Boundless Bio, Inc. 2Q 2026: Net loss $23.7M, EPS $(1.06) — 10-Q Summary - TradingView
Boundless Bio (Nasdaq: BOLD) plans Serapha merger and dividend - Stock Titan
Boundless Bio, Inc. Revenue Breakdown – NASDAQ:BOLD - TradingView
Boundless Bio Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Boundless Bio Inc (BOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Boundless Bio Inc (BOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
BOLD|Boundless Bio Inc|Price:2.485|Chg%:-0.085 - TradingKey
Boundless Bio Inc (BOLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Boundless Bio Inc (BOLD) Institutional Confidence - TradingKey
Boundless Bio Inc (BOLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Boundless Bio Inc (BOLD) Balance Sheet - tradingkey.com
BOLD|Boundless Bio Inc|Price:2.580|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Boundless Bio Inc (BOLD) Income Statement - TradingKey
Boundless Bio Inc (BOLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Boundless Bio director Kevin Tang buys $11,865 in shares By Investing.com - Investing.com South Africa
Major Investor Quietly Boosts Stake in Emerging Biotech Player - TipRanks
Form 4 Boundless Bio Inc For: 21 July By Investing.com - Investing.com South Africa
Boundless Bio 10% owner Kevin Tang acquires $11,876 in common shares - Bitget
Boundless Bio director Kevin Tang buys $11,865 in shares - Investing.com
Boundless Bio (NASDAQ: BOLD) major Tang Capital holder adds 4,863 shares - Stock Titan
Boundless Bio Inc. (BOLD) Q1 2026 Earnings: EPS Misses Estimates, Shares Dip Amid Clinical-Stage Challenges - dars.gov.et
Boundless Bio Inc. (BOLD) Holds Near Support After Modest DeclineBuyback Factor - dars.gov.et
Tang Capital’s Kevin Tang reports $154,586 Boundless Bio common share purchase - Bitget
Boundless Bio: ten percent owner Kevin Tang buys $155,645 By Investing.com - Investing.com South Africa
Boundless Bio: ten percent owner Kevin Tang buys $155,645 - Investing.com
63,969 shares bought by Tang Capital in Boundless Bio, Inc. (BOLD) - Stock Titan
Form 4 Boundless Bio Inc For: 13 July By Investing.com - Investing.com Nigeria
Tang capital management, Kevin Tang buy $222k Boundless Bio stock By Investing.com - Investing.com Nigeria
Tang capital management, Kevin Tang buy $222k Boundless Bio stock - Investing.com
Boundless Bio (BOLD) Gains 2.45% as Shares Approach Key ResistanceRelative Volume - DonanımHaber
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) By Investing.com - Investing.com Nigeria
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) - Investing.com
Boundless Bio Inc. (BOLD) Holds Steady at $2.50: Navigating Key Support and Resistance LevelsTechnical Analysis - DonanımHaber
Boundless Bio to merge with Serapha Bio in reverse merger; shares surge - MSN
Form 4 Boundless Bio Inc For: 6 July By Investing.com - Investing.com Nigeria
Boundless Bio ten percent owner Kristina Burow sells $39,840 in stock - Investing.com
Arch venture funds sell $39,840 in Boundless Bio stock - Investing.com
Form 4 Boundless Bio Inc For: 6 July - Investing.com India
Arch venture funds sell $39,840 in Boundless Bio stock By Investing.com - Investing.com Canada
ARCH funds, insiders trade 16,000 Boundless Bio (BOLD) shares - Stock Titan
16K Boundless Bio (BOLD) shares sold by ARCH funds post-exercise - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Boundless Bio Inc. (BOLD) Sees Mild Uptick as Biotech Sector Holds SteadyResistance Breakout Stocks - dars.gov.et
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):